Cited by 294Tuberculosis Research and EpidemiologyImmune responses and vaccinationsInfectious Diseases and Tuberculosis

The DOI matches its Crossref record; 121 of the 121 references it cites were found in a registry or an index.

Advancing host-directed therapy for tuberculosis

Wallis, Robert S., Hafner, Richard·2015·Nature Reviews Immunology

Open this paper in CoChat — free account

Abstract

Improved treatments are needed for nearly all forms of Mycobacterium tuberculosis infection. Adjunctive host-directed therapies have the potential to shorten tuberculosis treatment duration, prevent resistance and reduce lung injury by promoting autophagy, antimicrobial peptide production and other macrophage effector mechanisms, as well as by modifying specific mechanisms that cause lung inflammation and matrix destruction. The range of candidates is broad, including several agents approved for other clinical indications that are ready for evaluation in Phase II clinical trials. The promise of new and existing host-directed therapies that could accelerate response and improve tuberculosis treatment outcomes is discussed in this Opinion article.

Integrity signals

Registry

Crossref · 10.1038/nri3813

Cites

121 of 121 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response
Liu, P. T., Stenger, S., Li, H., Wenzel, L., Tan, B. H., Krutzik, S. R., Ochoa, M. T., Schauber, J., Wu, K., Meinken, C., et al. (2006) · Science · doi:10.1126/science.1123933 · Cited by 3,924
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S. K., Wise, R. P., Mirabile‐Levens, E., Kasznica, J. M., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,683
Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy
Egan, D. F., Shackelford, D. B., Mihaylova, M. M., Gelino, S., Kohnz, R. A., Mair, W., Vasquez, D. S., Joshi, A., Gwinn, D. M., Taylor, R., et al. (2011) · Science · doi:10.1126/science.1196371 · Cited by 2,600
Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347
Autophagy Is a Defense Mechanism Inhibiting BCG and Mycobacterium tuberculosis Survival in Infected Macrophages
Gutierrez, M. G., Master, S. S., Singh, S. B., Taylor, G. A., Colombo, M. I., & Deretic, V. (2004) · Cell · doi:10.1016/j.cell.2004.11.038 · Cited by 2,252
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G. (2014) · Science · doi:10.1126/science.1244917 · Cited by 1,583
A Mutation in the Interferon-γ –Receptor Gene and Susceptibility to Mycobacterial Infection
Newport, M. J., Huxley, C. M., Huston, S., Hawrylowicz, C. M., Oostra, B. A., Williamson, R., & Levin, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352602 · Cited by 1,198
Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.
Sampaio, E. P., Sarno, E. N., Gallily, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.173.3.699 · Cited by 1,191
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,171
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M. A., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & ZINSMEISTER, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 906
Identification of a candidate therapeutic autophagy-inducing peptide
Shoji-Kawata, S., Sumpter, R., Leveno, M., Campbell, G. R., Zou, Z., Kinch, L., Wilkins, A. D., Sun, Q., Pallauf, K., MacDuff, D., et al. (2013) · Nature · doi:10.1038/nature11866 · Cited by 760
Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk
Mayer-Barber, K. D., Andrade, B. B., Oland, S. D., Amaral, E. P., Barber, D. L., Gonzales, J., Derrick, S. C., Shi, R., Kumar, N. P., Wei, W., et al. (2014) · Nature · doi:10.1038/nature13489 · Cited by 757
Extracellular M. tuberculosis DNA Targets Bacteria for Autophagy by Activating the Host DNA-Sensing Pathway
Watson, R. O., Manzanillo, P. S., & Cox, J. S. (2012) · Cell · doi:10.1016/j.cell.2012.06.040 · Cited by 755
Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
Karim, S. S. A., Naidoo, K., Grobler, A. C., Padayatchi, N., Baxter, C., Gray, A., Gengiah, T. N., Nair, G., Bamber, S., Singh, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905848 · Cited by 662
Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists
Carmona, L., Gómez-Reino, J. J., Rodrı́guez-Valverde, V., Montero, D., Pascual, E., Mola, E. M., Carreño, L., Figueroa, M., & BIOBADASER Group (2005) · Arthritis & Rheumatism · doi:10.1002/art.21043 · Cited by 655
Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
Gillespie, S. H., Crook, A. M., McHugh, T. D., Mendel, C. M., Meredith, S. K., Murray, S. R., Pappas, F., Phillips, P. P. J., & Nunn, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407426 · Cited by 644
Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective french research axed on tolerance of biotherapies registry
Tubach, F., Salmon, D., Ravaud, P., Allanore, Y., Goupille, P., Bréban, M., Pallot‐Prades, B., Pouplin, S., Sacchi, A., Chichemanian, R.-M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24632 · Cited by 629
Structure-Function Analysis of STING Activation by c[G(2′,5′)pA(3′,5′)p] and Targeting by Antiviral DMXAA
Gao, P., Ascano, M., Zillinger, T., Wang, W., Dai, P., Serganov, A. A., Gaffney, B. L., Shuman, S., Jones, R. A., Deng, L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.07.023 · Cited by 612
Relationship of the Manifestations of Tuberculosis to CD4 Cell Counts in Patients with Human Immunodeficiency Virus Infection
Jones, B. E., Young, S. M. M., Antoniskis, D., Davidson, P. T., Kramer, F., & Barnes, P. F. (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/148.5.1292 · Cited by 586
Host Genotype-Specific Therapies Can Optimize the Inflammatory Response to Mycobacterial Infections
Tobin, D. M., Roca, F. J., Oh, S. F., McFarland, R., Vickery, T. W., Ray, J. P., Ko, D. C., Zou, Y., Bang, N. D., Chau, T. T. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.023 · Cited by 583
High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial
Martineau, A. R., Timms, P. M., Bothamley, G. H., Hanifa, Y., Islam, K., Claxton, A. P., Packe, G. E., Moore-Gillon, J. C., Darmalingam, M., Davidson, R. N., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61889-2 · Cited by 581
Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study
Badri, M., Wilson, D., & Wood, R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08904-3 · Cited by 552
Metformin as adjunct antituberculosis therapy
Singhal, A., Jie, L., Kumar, P., Hong, G. S., Leow, M. K.-S., Paleja, B., Tsenova, L., Kurepina, N., Chen, J., Zolezzi, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009885 · Cited by 547
Thalidomide in the treatment of lepra reactions
Sheskin, J. (1965) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt196563303 · Cited by 534
Accelerated Course of Human Immunodeficiency Virus Infection after Tuberculosis
Whalen, C., Horsburgh, C. R., Hom, D., Lahart, C., Simberkoff, M. S., & Ellner, J. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.1.7812542 · Cited by 532
Glucocorticoid use, other associated factors, and the risk of tuberculosis
Jick, S. S., Lieberman, E. S., Rahman, M. U., & Choi, H. K. (2006) · Arthritis Care & Research · doi:10.1002/art.21705 · Cited by 477
HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers
Sonnenberg, P., Murray, J., Glynn, J. R., Shearer, S., Kambashi, B. S., & Godfrey‐Faussett, P. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06712-5 · Cited by 435
Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response
Briken, V., Porcelli, S. A., Besra, G. S., & Kremer, L. (2004) · Molecular Microbiology · doi:10.1111/j.1365-2958.2004.04183.x · Cited by 432
High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis
Jindani, A., Harrison, T. S., Nunn, A., Phillips, P. P. J., Churchyard, G., Charalambous, S., Hatherill, M., Geldenhuys, H. D., McIlleron, H., Zvada, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314210 · Cited by 430
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trial
Clair, E. W. S., Wagner, C. L., Fasanmade, A. A., Wang, B., Schaible, T. F., Kavanaugh, A., & Keystone, E. C. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10302 · Cited by 416
A Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis
Merle, C. S., Fielding, K., Bah-Sow, O. Y., Gninafon, M., Lo, M. B., Mthiyane, T., Odhiambo, J. A., Amukoye, E., Bah, B., Kassa, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315817 · Cited by 399
Vitamin D as Supplementary Treatment for Tuberculosis
Wejse, C. M., Gomes, V. F., Rabna, P., Gustafson, P., Aaby, P., Lisse, I. M., Andersen, P. L., Glerup, H., & Sodemann, M. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200804-567oc · Cited by 396
Etanercept for the Treatment of Stage II and III Progressive Pulmonary Sarcoidosis
Utz, J. P., LIMPER, A. H., Kalra, S., Specks, U., Scott, J. P., Vuk-Pavlović, Z., & Schroeder, D. R. (2003) · CHEST Journal · doi:10.1378/chest.124.1.177 · Cited by 386
Macrophages in tuberculosis: friend or foe
Guirado, E., Schlesinger, L. S., & Kaplan, G. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-013-0388-2 · Cited by 331
Statin Therapy Reduces the Mycobacterium tuberculosis Burden in Human Macrophages and in Mice by Enhancing Autophagy and Phagosome Maturation
Parihar, S. P., Guler, R., Khutlang, R., Lang, D. M., Hurdayal, R., Mhlanga, M. M., Suzuki, H., Marais, A. D., & Brombacher, F. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit550 · Cited by 320
Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection
Renna, M., Schaffner, C., Brown, K., Shang, S., Henao-Tamayo, M. I., Hegyi, K., Grimsey, N. J., Cusens, D., Coulter, S., Cooper, J. F., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46095 · Cited by 318
Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment
Coussens, A. K., Wilkinson, R. J., Hanifa, Y., Nikolayevskyy, V., Elkington, P. T., Islam, K., Timms, P. M., Venton, T. R., Bothamley, G. H., Packe, G. E., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1200072109 · Cited by 310
The effect of vitamin D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion.
Ew, N., Amin, Z., & Rumende, C. M. (2006) · PubMed · Cited by 267
Macrophages Acquire Neutrophil Granules for Antimicrobial Activity against Intracellular Pathogens
Tan, B. H., Meinken, C., Bastian, M., Bruns, H., Legaspi, A., Ochoa, M. T., Krutzik, S. R., Bloom, B. R., Ganz, T., Modlin, R. L., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.3.1864 · Cited by 267
S100A8/A9 Proteins Mediate Neutrophilic Inflammation and Lung Pathology during Tuberculosis
Gopal, R., Monin, L., Torres‐García, D., Slight-Webb, S. R., Mehra, S., McKenna, K. C., Junecko, B. A. F., Reinhart, T. A., Kolls, J. K., Báez-Saldaña, R., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201304-0803oc · Cited by 266
Adjunctive Corticosteroid Therapy for Tuberculosis: A Critical Reappraisal of the Literature
Dooley, D. P., Carpenter, J. L., & Rademacher, S. (1997) · Clinical Infectious Diseases · doi:10.1086/515543 · Cited by 259
Mycobacterium tuberculosis Activates Human Macrophage Peroxisome Proliferator-Activated Receptor γ Linking Mannose Receptor Recognition to Regulation of Immune Responses
Rajaram, M. V. S., Brooks, M. N., Morris, J. D., Torrelles, J. B., Azad, A. K., & Schlesinger, L. S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000866 · Cited by 256
Identification of Host-Targeted Small Molecules That Restrict Intracellular Mycobacterium tuberculosis Growth
Stanley, S. A., Barczak, A. K., Silvis, M. R., Luo, S. S., Sogi, K., Vokes, M., Bray, M.-A., Carpenter, A. E., Moore, C. B., Siddiqi, N., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003946 · Cited by 251
A Trial of Mass Isoniazid Preventive Therapy for Tuberculosis Control
Churchyard, G. J., Fielding, K. L., Lewis, J. J., Coetzee, L., Corbett, E. L., Godfrey-Faussett, P., Hayes, R. J., Chaisson, R. E., & Grant, A. D. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1214289 · Cited by 238
A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis
Wallis, R. S., Kyambadde, P., Johnson, J. L., Horter, L., Kittle, R., Pohle, M., Ducar, C., Millard, M., Mayanja‐Kizza, H., Whalen, C. C., et al. (2004) · AIDS · doi:10.1097/00002030-200401230-00015 · Cited by 224
Self-citation
Ibuprofen Therapy Resulted in Significantly Decreased Tissue Bacillary Loads and Increased Survival in a New Murine Experimental Model of Active Tuberculosis
Vilaplana, C., Marzo, E., Tapia, G., Diaz, J., Garcia, V., & Cardona, P.-J. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit152 · Cited by 220
Granulomatous Infections Due to Tumor Necrosis Factor Blockade: Correction
Wallis, R. S., Broder, M. S., Wong, J., & Beenhouwer, D. O. (2004) · Clinical Infectious Diseases · doi:10.1086/424455 · Cited by 218
Self-citation
Letting SleepingdosLie: Does Dormancy Play a Role in Tuberculosis?
Chao, M. C., & Rubin, E. J. (2010) · Annual Review of Microbiology · doi:10.1146/annurev.micro.112408.134043 · Cited by 218
Imatinib-Sensitive Tyrosine Kinases Regulate Mycobacterial Pathogenesis and Represent Therapeutic Targets against Tuberculosis
Napier, R. J., Rafi, W., Cheruvu, M., Powell, K. R., Zaunbrecher, M. A., Bornmann, W. G., Salgame, P., Shinnick, T. M., & Kalman, D. (2011) · Cell Host & Microbe · doi:10.1016/j.chom.2011.09.010 · Cited by 210
Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa
Martineau, A. R., Nhamoyebonde, S., Oni, T., Rangaka, M. X., Marais, S., Bangani, N., Tsekela, R., Bashe, L., Azevedo, V. D., Caldwell, J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111825108 · Cited by 210
Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis
Critchley, J., Young, F., Orton, L., & Garner, P. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70321-3 · Cited by 209
A double-blind, placebo-controlled study of vitamin A and zinc supplementation in persons with tuberculosis in Indonesia: effects on clinical response and nutritional status
Karyadi, E., West, C. E., Schultink, W., Nelwan, R. H. H., Gross, R., Amin, Z., Dolmans, W. M. V., Schlebusch, H., & van der Meer, J. W. M. (2002) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/75.4.720 · Cited by 209
Increased Release of Interleukin-1 Beta, Interleukin-6, and Tumor Necrosis Factor-Alpha by Bronchoalveolar Cells Lavaged From Involved Sites in Pulmonary Tuberculosis
Law, K. F., Weiden, M. D., Harkin, T. J., Tchou-Wong, K.-M., Chi, C.-N., & Rom, W. N. (1996) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.153.2.8564135 · Cited by 192
Antibody-Mediated Immunity against Tuberculosis: Implications for Vaccine Development
Achkar, J. M., & Casadevall, A. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.02.009 · Cited by 181
Interaction of Pattern Recognition Receptors with Mycobacterium Tuberculosis
Mortaz, E., Adcock, I. M., Tabarsi, P., Masjedi, M. R., Mansouri, D., Velayati, A. A., Casanova, J., & Barnes, P. J. (2014) · Journal of Clinical Immunology · doi:10.1007/s10875-014-0103-7 · Cited by 180
Therapeutic Use of Infliximab in Tuberculosis to Control Severe Paradoxical Reaction of the Brain and Lymph Nodes
Blackmore, T., Manning, L. A., Taylor, W. J., & Wallis, R. S. (2008) · Clinical Infectious Diseases · doi:10.1086/592695 · Cited by 178
Self-citation
Chronic obstructive airways disease following treated pulmonary tuberculosis
WILLCOX, P. A., & Ferguson, A. D. (1989) · Respiratory Medicine · doi:10.1016/s0954-6111(89)80031-9 · Cited by 165
PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis
Chen, R. Y., Dodd, L. E., Lee, M., Paripati, P., Hammoud, D. A., Mountz, J. M., Jeon, D., Zia, N., Zahiri, H., Coleman, M. T., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009501 · Cited by 157
Doxycycline and HIV Infection Suppress Tuberculosis-induced Matrix Metalloproteinases
Walker, N. F., Clark, S. O., Oni, T., Andreu, N., Tezera, L. B., Singh, S., Saraiva, L., Pedersen, B., Kelly, D. L. F., Tree, J. A., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201110-1769oc · Cited by 144
Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial
Skrahin, A., Ahmed, R. K. S., Ferrara, G., Rane, L., Poiret, T., Isaikina, Y., Skrahina, A. M., Zumla, A. I., & Maeurer, M. J. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70234-0 · Cited by 143
L-arginine and Vitamin D Adjunctive Therapies in Pulmonary Tuberculosis: A Randomised, Double-Blind, Placebo-Controlled Trial
Ralph, A. P., Waramori, G., Pontororing, G. J., Kenangalem, E., Wiguna, A., Tjitra, E., Sandjaja, Lolong, D. B., Yeo, T. W., Chatfield, M. D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070032 · Cited by 141
Phenylbutyrate Induces Antimicrobial Peptide Expression
Steinmann, J., Halldórsson, S., Agerberth, B., & Gudmundsson, G. H. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00818-09 · Cited by 140
Immunoadjuvant Prednisolone Therapy for HIV‐Associated Tuberculosis: A Phase 2 Clinical Trial in Uganda
Mayanja‐Kizza, H., Jones‐López, E. C., Okwera, A., Wallis, R. S., Ellner, J. J., Mugerwa, R. D., & Whalen, C. C. (2005) · The Journal of Infectious Diseases · doi:10.1086/427995 · Cited by 137
Self-citation
Adjunctive Thalidomide Therapy for Childhood Tuberculous Meningitis: Results of a Randomized Study
Schoeman, J. F., Springer, P. E., van Rensburg, A. J., Swanevelder, S. A., Hanekom, W. A., Haslett, P. A. J., & Kaplan, G. (2004) · Journal of Child Neurology · doi:10.1177/088307380401900402 · Cited by 132
PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis
Coleman, M. T., Chen, R. Y., Lee, M., Lin, P. L., Dodd, L. E., Maiello, P. A., Via, L. E., Kim, Y., Marriner, G. A., Dartois, V. A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009500 · Cited by 131
Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosis
Byrne, S. T., Denkin, S. M., & Zhang, Y. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl486 · Cited by 131
Adalimumab Treatment of Life‐Threatening Tuberculosis
Wallis, R. S., van Vuuren, C., & Potgieter, S. (2009) · Clinical Infectious Diseases · doi:10.1086/598504 · Cited by 129
Self-citation
Pulmonary impairment after tuberculosis and its contribution to TB burden
Pasipanodya, J. G., McNabb, S. J. N., Hilsenrath, P. E., Bae, S., Lykens, K., Vecino, E., Munguia, G., Miller, T. L., Drewyer, G., & Weis, S. E. (2010) · BMC Public Health · doi:10.1186/1471-2458-10-259 · Cited by 126
A delicate dance: host response to mycobacteria
Huynh, K. K., Joshi, S. A., & Brown, E. J. (2011) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.06.002 · Cited by 126
Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi
Crampin, A. C., Mwaungulu, J. N., Mwaungulu, F. D., Mwafulirwa, D. T., Munthali, K., Floyd, S., Fine, P., & Glynn, J. R. (2010) · AIDS · doi:10.1097/qad.0b013e32832f51cf · Cited by 125
Clinical studies on the management of periodontal diseases utilizing subantimicrobial dose doxycycline (SDD)
Caton, J. G., & RYAN, M. E. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.12.003 · Cited by 125
Immunomodulation with Recombinant Interferon-γ1b in Pulmonary Tuberculosis
Dawson, R., Condos, R., Tse, D. B., Huie, M. L., Ress, S., Tseng, C., Brauns, C., Weiden, M. D., Hoshino, Y., Bateman, E. D., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006984 · Cited by 121
Simvastatin increases the in vivo activity of the first-line tuberculosis regimen
Skerry, C. M., Pinn, M. L., Bruiners, N., Pine, R. I., Gennaro, M. L., & Karakousis, P. C. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku166 · Cited by 119
Randomized Trial of Adjunctive Interleukin-2 in Adults with Pulmonary Tuberculosis
Johnson, J. L., Ssekasanvu, E., Okwera, A., Mayanja‐Kizza, H., Hirsch, C. S., Nakibali, J. G., Jankus, D. D., Eisenach, K. D., Boom, W. H., Ellner, J. J., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1359oc · Cited by 115
Abelson Tyrosine Kinase Controls Phagosomal Acidification Required for Killing of Mycobacterium tuberculosis in Human Macrophages
Bruns, H., Stegelmann, F., Fabri, M., Döhner, K., van Zandbergen, G., Wagner, M., Skinner, M., Modlin, R. L., & Stenger, S. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201538 · Cited by 112
Abl Kinases Regulate Autophagy by Promoting the Trafficking and Function of Lysosomal Components
Yogalingam, G., & Pendergast, A. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804543200 · Cited by 109
Metformin, an Antidiabetic Agent, Suppresses the Production of Tumor Necrosis Factor and Tissue Factor by Inhibiting Early Growth Response Factor-1 Expression in Human Monocytes in Vitro
Arai, M., Uchiba, M., Komura, H., Mizuochi, Y., Harada, N., & Okajima, K. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.164970 · Cited by 108
Phosphodiesterase-4 Inhibition Alters Gene Expression and Improves Isoniazid – Mediated Clearance of Mycobacterium tuberculosis in Rabbit Lungs
Subbian, S., Tsenova, L., O’Brien, P. E., Yang, G., Koo, M.-S., Peixoto, B., Fallows, D. A., Dartois, V. A., Muller, G. W., & Kaplan, G. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002262 · Cited by 94
Oral intake of phenylbutyrate with or without vitamin D3upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis
Mily, A., Rekha, R. S., Kamal, S. M. M., Akhtar, E., Sarker, P., Rahim, Z., Gudmundsson, G. H., Agerberth, B., & Raqib, R. (2013) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-13-23 · Cited by 92
Therapeutic Efficacy of High-Dose Intravenous Immunoglobulin inMycobacterium tuberculosisInfection in Mice
Roy, E., Stavropoulos, E., Brennan, J., Coade, S. B., Grigorieva, E., Walker, B., Dagg, B. M., Tascon, R. E., Lowrie, D. B., Colston, M. J., et al. (2005) · Infection and Immunity · doi:10.1128/iai.73.9.6101-6109.2005 · Cited by 90
The potential for disease modification in Crohn's disease
Assche, G. V., Vermeire, S. A. R. A., & Rutgeerts, P. J. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.220 · Cited by 86
Intractable Intracranial Tuberculous Infection Responsive to Thalidomide: Report of Four Cases
Schoeman, J. F., Fieggen, G. A. G., Seller, N., Mendelson, M., & Hartzenberg, B. H. (2006) · Journal of Child Neurology · doi:10.1177/08830738060210040801 · Cited by 85
Early innate immunity determines outcome of Mycobacterium tuberculosis pulmonary infection in rabbits
Subbian, S., Bandyopadhyay, N., Tsenova, L., O’Brien, P. E., Khetani, V., Kushner, N. L., Peixoto, B., Soteropoulos, P., Bader, J. S., Karakousis, P. C., et al. (2013) · Cell Communication and Signaling · doi:10.1186/1478-811x-11-60 · Cited by 84
Increased Interleukin-1 Production and Monocyte Suppressor Cell Activity Associated with Human Tuberculosis
Fujiwara, H., Kleinhenz, M. E., Wallis, R. S., & Ellner, J. J. (1986) · American Review of Respiratory Disease · doi:10.1164/arrd.1986.133.1.73 · Cited by 84
Self-citation
Inhibition of Mycobacterial GrowthIn Vitrofollowing Primary but Not Secondary Vaccination with Mycobacterium bovis BCG
Fletcher, H. A., Tanner, R., Wallis, R. S., Meyer, J., Manjaly, Z.-R., Harris, S. A., Satti, I., Silver, R. F., Hoft, D., Kampmann, B., et al. (2013) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00427-13 · Cited by 82
Self-citation
Phosphodiesterase 4 Inhibition Reduces Innate Immunity and Improves Isoniazid Clearance of Mycobacterium tuberculosis in the Lungs of Infected Mice
Koo, M.-S., Manca, C., Yang, G., O’Brien, P. E., Sung, N., Tsenova, L., Subbian, S., Fallows, D. A., Muller, G. W., Ehrt, S., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017091 · Cited by 75
Pentoxifylline Therapy in Human Immunodeficiency Virus--Seropositive Persons with Tuberculosis: A Randomized, Controlled Trial
Wallis, R. S., Nsubuga, P., Whalen, C., Mugerwa, R. D., Okwera, A., Oette, D. H., Jackson, J. B., Johnson, J. L., & Ellner, J. J. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/174.4.727 · Cited by 75
Self-citation
Whole Blood Bactericidal Activity during Treatment of Pulmonary Tuberculosis
Wallis, R. S., Vinhas, S. A., Johnson, J. L., Ribeiro, F. C., Palaci, M., Peres, R. L., Sá, R. T., Dietze, R., Chiunda, A. B., Eisenach, K. D., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/346053 · Cited by 75
Self-citation
Novel STAT1 Alleles in a Patient with Impaired Resistance to Mycobacteria
Kristensen, I. A., Veirum, J. E., Møller, B. K., & Christiansen, M. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9480-8 · Cited by 73
Successful Shortening of Tuberculosis Treatment Using Adjuvant Host-Directed Therapy with FDA-Approved Phosphodiesterase Inhibitors in the Mouse Model
Maïga, M., Agarwal, N., Ammerman, N. C., Gupta, R., Guo, H., Maiga, M. C., Lun, S., & Bishai, W. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030749 · Cited by 70
Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator
Gondcaille, C., Depreter, M., Fourcade, S., Lecca, M. R., Leclercq, S., Martin, P. G. P., Pineau, T., Cadepond, F., El‐Etr, M., Bertrand, N., et al. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200501036 · Cited by 70
Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro
Mahony, C. B., Erskine, L., Niven, J., Greig, N. H., Figg, W. D., & Vargesson, N. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307684110 · Cited by 69
Month 2 Culture Status and Treatment Duration as Predictors of Tuberculosis Relapse Risk in a Meta-Regression Model
Wallis, R. S., Wang, C., Meyer, D., & Thomas, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071116 · Cited by 66
Self-citation
Clinical and epidemiological characteristics of individuals resistant to M. tuberculosis infection in a longitudinal TB household contact study in Kampala, Uganda
Ma, N., Zalwango, S. K., Malone, L. L., Nsereko, M., Wampande, E. M., Thiel, B., Okware, B., Igo, R. P., Joloba, M. L., Mupere, E., et al. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-352 · Cited by 64
Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade
Wallis, R. S. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23285 · Cited by 63
Self-citation
Study of chemotherapy regimens of 5 and 7 months' duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India
Tuberculosis Research Centre (1983) · Tubercle · doi:10.1016/0041-3879(83)90032-6 · Cited by 62
Risk of Tuberculosis Reactivation With Tofacitinib (CP-690550)
Maïga, M., Lun, S., Guo, H., Winglee, K., Ammerman, N. C., & Bishai, W. R. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis269 · Cited by 58
Adjuvant Host-Directed Therapy with Types 3 and 5 but Not Type 4 Phosphodiesterase Inhibitors Shortens the Duration of Tuberculosis Treatment
Maïga, M., Ammerman, N. C., Maiga, M. C., Tounkara, A., Siddiqui, S., Polis, M., Murphy, R. L., & Bishai, W. R. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit187 · Cited by 56
Tuberculous Meningitis-Related Optic Neuritis: Recovery of Vision With Thalidomide in 4 Consecutive Cases
Schoeman, J. F., Andronikou, S., Stefan, D. C., Freeman, N., & van Toorn, R. (2010) · Journal of Child Neurology · doi:10.1177/0883073809350507 · Cited by 55
Appropriate DevR (DosR)-Mediated Signaling Determines Transcriptional Response, Hypoxic Viability and Virulence of Mycobacterium tuberculosis
Majumdar, S. D., Vashist, A., Dhingra, S., Gupta, R., Singh, A., Challu, V. K., Ramanathan, V. D., Kumar, P., & Tyagi, J. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035847 · Cited by 53
Serum MMPs 7–9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease
Mäkitalo, L., Rintamäki, H., Tervahartiala, T. I., Sorsa, T. A., & Kolho, K. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.677954 · Cited by 53
Large-scale imatinib dose–concentration–effect study in CML patients under routine care conditions
Gotta, V., Bouchet, S., Widmer, N., Schuld, P., Decosterd, L. A., Buclin, T., Mahon, F., Csajka, C., & Molimard, M. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.03.023 · Cited by 50
Pharmacological modulation of TNF production in macrophages.
Lin, H.-I., Chu, S.-J., Wang, D., & Feng, N. (2004) · PubMed · Cited by 50
Role of autophagy in the host response to microbial infection and potential for therapy
Fabri, M., Realegeno, S. E., Jo, E., & Modlin, R. L. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.10.010 · Cited by 49
The effects of statin use on the development of tuberculosis among patients with diabetes mellitus
Kang, Y. A., Choi, N., Seong, J.-M., Heo, E. Y., Koo, B. K., Hwang, S.-S., Park, B.-J., Yim, J.-J., & Lee, C.-H. (2014) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.13.0854 · Cited by 45
Failure to Control Growth of Mycobacteria in Blood from Children Infected with Human Immunodeficiency Virus and Its Relationship to T Cell Function
Tena, G. N., Young, D., Eley, B., Henderson, H., Nicol, M. P., Levin, M., & Kampmann, B. (2003) · The Journal of Infectious Diseases · doi:10.1086/374799 · Cited by 44
Improved Control of Tuberculosis and Activation of Macrophages in Mice Lacking Protein Kinase R
Wu, K., Koo, J. T., Jiang, X., Chen, R., Cohen, S. N., & Nathan, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030512 · Cited by 41
Longevity loss among cured tuberculosis patients and the potential value of prevention
Hoger, S., Lykens, K., Beavers, S. F., Katz, D., & Miller, T. L. (2014) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.14.0242 · Cited by 41
Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology
Turner, J., Frank, A. A., Brooks, J. V., Marietta, P., & Orme, I. M. (2001) · Immunology · doi:10.1046/j.1365-2567.2001.01161.x · Cited by 35
Recent development in pleiotropic effects of statins on cardiovascular disease through regulation of transforming growth factor-beta superfamily
Ma, S., & Ma, C. C.-H. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.05.004 · Cited by 35
The Protein Kinase Double-Stranded RNA-Dependent (PKR) Enhances Protection against Disease Cause by a Non-Viral Pathogen
Ogolla, P. S., Portillo, J. C., White, C. L., Patel, K., Lamb, B. T., Sen, G. C., & Subauste, C. S. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003557 · Cited by 33
Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)
Tijono, S., Guo, K., Henare, K. L., Palmer, B. D., Wang, L.-C. S., Albelda, S. Μ., & Ching, L. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.101 · Cited by 33
Assessment of long term status of sputum positive pulmonary TB patients successfully treated with short course chemotherapy.
Rekha, V. V. B., Ramachandran, R., Rao, K. V., Rahman, F., Adhilakshmi, A. R., Kalaiselvi, D., Murugesan, P., Sundaram, V., & Narayanan, P. R. (2009) · PubMed · Cited by 29
Vitamin D3 and phenylbutyrate promote development of a human dendritic cell subset displaying enhanced antimicrobial properties
van der Does, A. M., Kenne, E. M., Koppelaar, E., Agerberth, B., & Lindbom, L. (2014) · Journal of Leukocyte Biology · doi:10.1189/jlb.1013549 · Cited by 28
The after-history of pulmonary tuberculosis. VI. The first fifteen years following diagnosis.
Alling, D. W., & Bosworth, E. B. (1960) · PubMed · doi:10.1164/arrd.1960.81.6.839 · Cited by 24
Assessment of Serum IL-1, IL-2 and IFN-γ Levels in Untreated Pulmonary Tuberculosis Patients: Role in Pathogenesis
Katti, M. K. (2011) · Archives of Medical Research · doi:10.1016/j.arcmed.2011.04.012 · Cited by 23
Performance of the MTBDRsl assay in Georgia
Tukvadze, N., Bablishvili, N., Apsindzelashvili, R., Blumberg, H. M., & Kempker, R. R. (2014) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.13.0468 · Cited by 20
Corticosteroid Effects on Sputum Culture in Pulmonary Tuberculosis: A Meta-Regression Analysis
Wallis, R. S. (2014) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofu020 · Cited by 18
Self-citation
CORTICOSTEROIDS IN PULMONARY TUBERCULOSIS. I. OVER-ALL RESULTS IN MADISON-MINNEAPOLIS VETERANS ADMINISTRATION HOSPITALS STEROID STUDY.
Johnson, J. R., Taylor, B. C., Morrissey, J. F., Jenne, J. W., & McDonald, F. (1965) · PubMed · doi:10.1164/arrd.1965.92.3.376 · Cited by 16
Pentoxifylline in Human Immunodeficiency Virus– Positive Tuberculosis: Safety at 4 Years
Wallis, R. S., Johnson, J. L., Okwera, A., Nsubuga, P., Whalen, C. C., Mugerwa, R. D., & Ellner, J. J. (1998) · The Journal of Infectious Diseases · doi:10.1086/314528 · Cited by 13
Self-citation

Flagged first, then by citations

Research works printed but not linked: 2

Trafford, G. et al. Anti-TNF therapy for severe CNS tuberculosis causing blindness. Eur. Conf. Clin. Micro. Infect. Dis. [online] , (2013).
Winthrop, K. L. et al. Tuberculosis and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheum. Abstr. 64 (Suppl. 10), 1278 (2012).

Sorted by citations

Host-directed therapies for bacterial and viral infections
Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S., & Bartenschlager, R. F. W. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.162 · Cited by 869
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Heterogeneity in tuberculosis
Cadena, A. M., Fortune, S. M., & Flynn, J. L. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.69 · Cited by 502
A major role for ferroptosis in Mycobacterium tuberculosis –induced cell death and tissue necrosis
Amaral, E. P., Costa, D. L., Namasivayam, S., Riteau, N., Kamenyeva, O., Mittereder, L., Mayer-Barber, K. D., Andrade, B. B., & Sher, A. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181776 · Cited by 464
Dynamic balance of pro‐ and anti‐inflammatory signals controls disease and limits pathology
Cicchese, J. M., Evans, S., Hult, C., Joslyn, L. R., Wessler, T., Millar, J. A., Marino, S., Cilfone, N. A., Mattila, J. T., Linderman, J. J., et al. (2018) · Immunological Reviews · doi:10.1111/imr.12671 · Cited by 344

See all 294

Authors: Wallis, R. S., & Hafner, R.
Affiliations: Aurum Institute (ZA)
National Institutes of Health (US)
Corresponding author: Wallis, Robert S.
ORCID: Wallis, Robert S.
Hafner, Richard
Venue: Nature Reviews Immunology
Publisher: Springer Science and Business Media LLC
Published: 2015-03-13
Volume: 15
Issue: 4
Pages: 255-263
ISSN: 1474-1733 (ISSN-L)
1474-1741
DOI: 10.1038/nri3813
OpenAlex: W1980411188
Cited by: 291
References: 121
Citations by year: 2026: 20 · 2025: 13 · 2024: 14 · 2023: 16 · 2022: 19 · 2021: 26 · 2020: 34 · 2019: 39 · 2018: 33 · 2017: 35 · 2016: 28 · 2015: 14
FWCI: 5.57
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Immunology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health
U.S. Public Health Service (HHSN272201200009C)
Topics: Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
Keywords: tuberculosis, host-directed therapy, Mycobacterium tuberculosis, adjunctive therapy, autophagy, antimicrobial peptides, lung injury, treatment duration, antimicrobial resistance, lung inflammation
MeSH terms: Humans, Immunity, Inflammation, Mycobacterium tuberculosis, Tuberculosis, Host-Pathogen Interactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Advancing host-directed therapy for tuberculosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks